Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

Journal of the American College of Cardiology

Volumn 41, Issue 7, 2003, Pages 1148-1155

  Flack, John M ^a   Oparil, Suzanne ^b   Pratt, J Howard ^c   Roniker, Barbara ^d   Garthwaite, Susan ^d   Kleiman, Jay H ^d   Yang, Yonghong ^d   Krause, Scott L ^d   Workman, Diane ^d   Saunders, Elijah ^e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b and Clinical Center   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; EPLERENONE; LOSARTAN; PLACEBO; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MENTAL DISEASE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OUTCOMES RESEARCH; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0037414091     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00054-8     Document Type: Article

References (26)

1. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep 1999;47:1-104.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.
3. Hall WD, Ferrario CM, Moore M, et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 1997;313:195-209.
4. He FJ, Markandu ND, Sagnella GA, MacGregor GA. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998;32:820-4.
5. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
6. Flack J, Hamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. J Hypertens 1999;17 Suppl 1:S19-24.
7. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21.
8. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997;29:641-50.
9. Preston RA, Materson BJ, Reda DJ, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998;280:1168-72.
10. Duncan K, Ramappa P, Thornburg R, et al. The influence of urinary albumin excretion and estimated glomerular filtration rate on blood pressure response in drug-treated hypertensive patients in an academic hypertension clinic (abstr). Am J Hypertens 2001;14:196A.
11. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Arch Intern Med 2000;160:825-31.
12. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995;17:911-23.
13. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.
14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
15. deGasparo M. Antialdosterones: incidence and prevention of sexual side effects. J Ster Biochem 1989;32:223-7.
16. Rocha R, Stier CT Jr., Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
17. McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild-to-moderate hypertension. Clin Cardiol 2001;24:66-72.
18. Venter CP, Joubert PH. Ethnic differences in response to beta 1-adrenoceptor blockade by propranolol. J Cardiovasc Pharmacol 1984;6:361-4.
19. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-13.
20. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995;26:124-30.
21. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
22. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-86.
23. Camargo MJ, von Lutterotti N, Campbell WG Jr., et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993;11:31-40.
24. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-8.
25. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
26. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.